Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination

Simple item page
dc.contributor.authorSisteré-Oró, Marta
dc.contributor.authorAndrade, Naína
dc.contributor.authorWortmann, Diana D. J.
dc.contributor.authorDu, Juan
dc.contributor.authorGarcia Giralt, Natàlia
dc.contributor.authorGonzález Cao, María
dc.contributor.authorGüerri Fernández, Roberto
dc.contributor.authorMeyerhans, Andreas
dc.date.accessioned2022-11-14T07:13:24Z
dc.date.available2022-11-14T07:13:24Z
dc.date.issued2022
dc.description.abstractIndividuals infected with the human immunodeficiency virus type 1 (HIV-1) belong to the group of people most vulnerable to SARS-CoV-2 infections and the associated disease COVID-19. Here we describe SARS-CoV-2-specific antibody and cellular immune responses in a small cohort of immunological non-responder HIV-1 patients (HIV-INRs) after receiving the COVID-19 mRNA-based BioNTech/Pfizer vaccine. Compared to the control group of vaccinated healthy individuals that all developed a virus-specific immune response, 5 of 10 vaccinated HIV-1 patients showed insufficient immune responses. The lack of response was not directly correlated with patients CD4 cell counts. Three of the five non-responders that agreed to receive a booster vaccination subsequently generated a virus-specific response. Thus, even HIV-INRs can be efficiently vaccinated against COVID-19 but may require a follow-up by virus-specific immune monitoring to guarantee clinical vaccine benefits.
dc.description.sponsorshipThe authors are supported by Spanish Melanoma Group Grant (GEM) (III Beca GEM para Grupos Emergentes), the Spanish Ministry of Science and Innovation grant no. PID2019-106323RB-I00 AEI//10.13039/501100011033, the “Unidad de Excelencia María de Maeztu”, funded by the MCIN and the AEI (DOI: 10.13039/501100011033); Ref: CEX2018-000792-M and by a FIS Project “PI19/00019” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union.
dc.format.mimetypeapplication/pdf
dc.identifier.citationSisteré-Oró M, Andrade N, Wortmann DDJ, Du J, Garcia-Giralt N, González-Cao M, Güerri-Fernández R, Meyerhans A. Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination. Front Immunol. 2022 Aug 26;13:994173. DOI: 10.3389/fimmu.2022.994173
dc.identifier.doihttp://dx.doi.org/10.3389/fimmu.2022.994173
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/10230/54830
dc.language.isoeng
dc.publisherFrontiers
dc.relation.ispartofFront Immunol. 2022 Aug 26;13:994173
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2PE/PID2019-106323RB-I00
dc.rights© 2022 Sisteré-Oró, Andrade, Wortmann, Du, Garcia-Giralt, González-Cao, Güerri-Fernández and Meyerhans. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.keywordCOVID-19 vaccination
dc.subject.keywordHIV-1
dc.subject.keywordSARS-CoV-2
dc.subject.keywordImmunological non-responder (INR)
dc.subject.keywordImmunosuppression
dc.titleAnti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sistere_fi_anti.pdf
Size:
1021.56 KB
Format:
Adobe Portable Document Format
Download

Collections

License

Rights